174 related articles for article (PubMed ID: 34353313)
21. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
22. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
Bhatt RS; Landis DM; Zimmer M; Torregrossa J; Chen S; Sukhatme VP; Iliopoulos O; Balk S; Bubley GJ
BJU Int; 2008 Aug; 102(3):358-63. PubMed ID: 18394010
[TBL] [Abstract][Full Text] [Related]
24. Targeting the HIF2-VEGF axis in renal cell carcinoma.
Choueiri TK; Kaelin WG
Nat Med; 2020 Oct; 26(10):1519-1530. PubMed ID: 33020645
[TBL] [Abstract][Full Text] [Related]
25. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
26. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
29. HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC.
Cancer Discov; 2018 Feb; 8(2):OF6. PubMed ID: 29330266
[TBL] [Abstract][Full Text] [Related]
30. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
31. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.
Kondo K; Kim WY; Lechpammer M; Kaelin WG
PLoS Biol; 2003 Dec; 1(3):E83. PubMed ID: 14691554
[TBL] [Abstract][Full Text] [Related]
32. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
[TBL] [Abstract][Full Text] [Related]
33. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
Li L; Zhang L; Zhang X; Yan Q; Minamishima YA; Olumi AF; Mao M; Bartz S; Kaelin WG
Mol Cell Biol; 2007 Aug; 27(15):5381-92. PubMed ID: 17526729
[TBL] [Abstract][Full Text] [Related]
35. HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Ma Y; Joyce A; Brandenburg O; Saatchi F; Stevens C; Toffessi Tcheuyap V; Christie A; Do QN; Fatunde O; Macchiaroli A; Wong SC; Woolford L; Yousuf Q; Miyata J; Carrillo D; Onabolu O; McKenzie T; Mishra A; Hardy T; He W; Li D; Ivanishev A; Zhang Q; Pedrosa I; Kapur P; Schluep T; Kanner SB; Hamilton J; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(24):5405-5418. PubMed ID: 36190432
[TBL] [Abstract][Full Text] [Related]
36. HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
Micucci C; Matacchione G; Valli D; Orciari S; Catalano A
Br J Cancer; 2015 Oct; 113(8):1178-85. PubMed ID: 26439684
[TBL] [Abstract][Full Text] [Related]
37. Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.
Nagaprashantha LD; Talamantes T; Singhal J; Guo J; Vatsyayan R; Rauniyar N; Awasthi S; Singhal SS; Prokai L
PLoS One; 2013; 8(8):e71654. PubMed ID: 23940778
[TBL] [Abstract][Full Text] [Related]
38. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α.
Schöning JP; Monteiro M; Gu W
Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):153-161. PubMed ID: 27809360
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
